Cytosorbents (NASDAQ: CTSO) and Hansen Medical (NASDAQ:HNSN) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, institutional ownership, earnings and analyst recommendations.
Earnings and Valuation
This table compares Cytosorbents and Hansen Medical’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cytosorbents||$9.53 million||23.48||-$11.93 million||($0.38)||-20.53|
Institutional and Insider Ownership
9.5% of Cytosorbents shares are owned by institutional investors. 5.6% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Cytosorbents and Hansen Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for Cytosorbents and Hansen Medical, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cytosorbents presently has a consensus price target of $10.65, indicating a potential upside of 36.54%.
Cytosorbents beats Hansen Medical on 7 of the 9 factors compared between the two stocks.
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
About Hansen Medical
Hansen Medical, Inc. is engaged in the development and marketing of medical devices. The Company develops, manufactures and sells a range of medical robotics designed for positioning, manipulation and stable control of catheters and catheter-based technologies. Its products include Sensei Robotic Catheter System (Sensei system), Artisan Extend Control Catheter, CoHesion 3D Visualization Module and Magellan System. Its Sensei system allows physicians to navigate catheters in interventional procedures within the atrial heart chambers. Its disposable Artisan Extend catheter assembly consists of a telescoping set of control catheters. Its CoHesion 3D Visualization Module is a software interface between its Sensei system and the St. Jude Medical EnSite System for Electro-Physiology procedures. The Magellan System controls the Magellan Robotic Catheter, which is a telescoping, steerable catheter designed to facilitate remote catheter navigation and vessel cannulation.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.